Guanabenz
This article needs additional citations for verification. (September 2014) |
Clinical data | |
---|---|
Trade names | Wytensin |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a686003 |
ATC code |
|
Pharmacokinetic data | |
Protein binding | 90% |
Elimination half-life | 6 hours |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an
The most common side effects during guanabenz therapy are
Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.
Research
Guanabenz also has some anti-inflammatory properties in different pathological situations, including multiple sclerosis.[4]
Guanabenz was found in one study to exert an inhibitory effect by decreasing the abundance of the enzyme CH25H, a cholesterol hydroxylase linked to antiviral immunity. Therefore, it is suggested that the drug and similar compounds could be used to treat type I interferon-dependent pathologies and that the CH25H enzyme could be a therapeutic target to control these diseases,[5] including amyotrophic lateral sclerosis.
See also
References
- S2CID 2139809.[permanent dead link]
- PMID 6599714.[permanent dead link]
- ^ "Guanabenz | The Merck Index Online". www.rsc.org. Retrieved 2023-04-17.
- PMID 25766071.
- S2CID 13680678.